These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 38439834)

  • 1. Gene therapy in glioblastoma multiforme: Can it be a role changer?
    Rayati M; Mansouri V; Ahmadbeigi N
    Heliyon; 2024 Mar; 10(5):e27087. PubMed ID: 38439834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent Advances in the Therapeutic Strategies of Glioblastoma Multiforme.
    Aldoghachi AF; Aldoghachi AF; Breyne K; Ling KH; Cheah PS
    Neuroscience; 2022 May; 491():240-270. PubMed ID: 35395355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.
    Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R
    Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vectors for Glioblastoma Gene Therapy: Viral & Non-Viral Delivery Strategies.
    Caffery B; Lee JS; Alexander-Bryant AA
    Nanomaterials (Basel); 2019 Jan; 9(1):. PubMed ID: 30654536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.
    van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE
    Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A narrative review of research progress on drug therapies for glioblastoma multiforme.
    Zheng X; Tang Q; Ren L; Liu J; Li W; Fu W; Wang J; Du G
    Ann Transl Med; 2021 Jun; 9(11):943. PubMed ID: 34350258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in Glioblastoma Therapy: An Update on Current Approaches.
    Angom RS; Nakka NMR; Bhattacharya S
    Brain Sci; 2023 Oct; 13(11):. PubMed ID: 38002496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic Monoclonal Antibodies Delivery for the Glioblastoma Treatment.
    Sousa F; Moura RP; Moreira E; Martins C; Sarmento B
    Adv Protein Chem Struct Biol; 2018; 112():61-80. PubMed ID: 29680243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advanced biomaterials for human glioblastoma multiforme (GBM) drug delivery.
    Nozhat Z; Heydarzadeh S; Shahriari-Khalaji M; Wang S; Iqbal MZ; Kong X
    Biomater Sci; 2023 Jun; 11(12):4094-4131. PubMed ID: 37073998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patients.
    Paff M; Alexandru-Abrams D; Hsu FP; Bota DA
    Hum Vaccin Immunother; 2014; 10(11):3322-31. PubMed ID: 25625931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of Therapies for Glioblastoma (GBM) Using Nanoparticle-based Delivery Systems.
    Wiwatchaitawee K; Quarterman JC; Geary SM; Salem AK
    AAPS PharmSciTech; 2021 Feb; 22(2):71. PubMed ID: 33575970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment.
    Pearson JRD; Cuzzubbo S; McArthur S; Durrant LG; Adhikaree J; Tinsley CJ; Pockley AG; McArdle SEB
    Front Immunol; 2020; 11():582106. PubMed ID: 33178210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small Molecule Immunomodulators as Next-Generation Therapeutics for Glioblastoma.
    Abdel-Rahman SA; Gabr M
    Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38275876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid-based nanoparticles to address the limitations of GBM therapy by overcoming the blood-brain barrier, targeting glioblastoma stem cells, and counteracting the immunosuppressive tumor microenvironment.
    Zhao C; Zhu X; Tan J; Mei C; Cai X; Kong F
    Biomed Pharmacother; 2024 Feb; 171():116113. PubMed ID: 38181717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
    Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
    Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging treatment strategies for glioblastoma multiforme.
    Carlsson SK; Brothers SP; Wahlestedt C
    EMBO Mol Med; 2014 Nov; 6(11):1359-70. PubMed ID: 25312641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Challenges and Opportunities in Treating Glioblastoma.
    Shergalis A; Bankhead A; Luesakul U; Muangsin N; Neamati N
    Pharmacol Rev; 2018 Jul; 70(3):412-445. PubMed ID: 29669750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular targeted therapy: A new avenue in glioblastoma treatment.
    El Atat O; Naser R; Abdelkhalek M; Habib RA; El Sibai M
    Oncol Lett; 2023 Feb; 25(2):46. PubMed ID: 36644133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of nanoparticles for drug delivery in glioblastoma multiforme.
    Jain KK
    Expert Rev Neurother; 2007 Apr; 7(4):363-72. PubMed ID: 17425491
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.